Inflammatory arthritis is treated with medications that calm the immune system and slow joint damage, combined with lifestyle changes that protect your joints over time. Unlike osteoarthritis, which results from wear and tear, inflammatory arthritis involves an overactive immune system attacking your own joint tissue. That distinction matters because it means treatment focuses on controlling inflammation at its source, not just managing pain.
The most important thing to know: early treatment makes a significant difference. Research consistently shows that the first two years after disease onset represent a critical window where aggressive treatment has the greatest potential to prevent irreversible joint damage and disability. Starting effective therapy within this window leads to less bone erosion and better long-term function than waiting.
How Disease-Modifying Drugs Work
The backbone of inflammatory arthritis treatment is a class of medications called disease-modifying antirheumatic drugs, or DMARDs. These don’t just relieve symptoms. They slow or stop the underlying immune process that destroys cartilage and bone. There are three main categories, and your doctor will typically step through them based on how well you respond.
Traditional DMARDs have broad effects on the immune system. They’ve been used for decades and remain the standard first-line treatment for most forms of inflammatory arthritis, including rheumatoid arthritis and psoriatic arthritis. Most people start here, and many achieve good disease control without needing anything more.
Biologic DMARDs are genetically engineered proteins that block specific components of the immune system rather than suppressing it broadly. Some target a protein called TNF, which drives inflammation in joint tissue. Others block different immune signaling molecules involved in conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Biologics are typically added when traditional DMARDs alone aren’t enough.
The newest option, targeted small-molecule DMARDs (JAK inhibitors), works inside immune cells to block precise signaling pathways. These are taken as pills rather than injections. However, the FDA requires their strongest safety warning on these medications due to increased risks of serious heart-related events, cancer, blood clots, and death identified in clinical trials. Because of these risks, JAK inhibitors are generally reserved for people who haven’t responded to or can’t tolerate biologic therapy, particularly those with cardiovascular risk factors or a history of smoking.
What Starting Treatment Looks Like
For rheumatoid arthritis, the most common starting approach involves a traditional DMARD taken once weekly. A typical starting dose is around 15 mg per week by mouth, with gradual increases of about 5 mg per month until you reach the most effective dose you can tolerate, often somewhere between 20 and 30 mg per week. Research shows this moderate-start, steady-escalation approach balances effectiveness against side effects better than either starting very low or jumping straight to high doses.
Higher starting doses do produce faster results, but they also cause more gastrointestinal side effects like nausea. Studies found that about 9% of people need to reduce their dose due to side effects regardless of where they start, and most people settle into an effective, tolerable dose of around 17 to 20 mg per week. If pills aren’t controlling your disease well enough, switching to injections under the skin can improve how much medication your body actually absorbs.
You’ll also likely take folic acid supplements alongside your DMARD to reduce side effects, and you’ll need regular blood tests to monitor your liver function. These visits also let your rheumatologist track your disease activity and adjust treatment. The goal is remission or the lowest possible disease activity, a strategy called “treat to target” that produces better outcomes than simply treating symptoms as they arise.
When Biologics Enter the Picture
If a traditional DMARD at an adequate dose doesn’t bring your disease under control after several months, your rheumatologist will likely recommend adding or switching to a biologic. The most commonly used biologics target TNF, and there are now several options available, including versions delivered by self-injection at home every one to two weeks.
Other biologics work through different mechanisms. Some block an immune signaling molecule called IL-6, which plays a central role in the widespread inflammation that causes fatigue and elevated blood markers. Others reduce immune cell activity by interfering with the way certain white blood cells communicate. One targets a specific type of immune cell called B cells, which produce the antibodies that attack joint tissue. Your rheumatologist will choose based on your specific type of inflammatory arthritis, your other health conditions, and practical considerations like whether you prefer injections or infusions.
All biologics carry some increased risk of infection, since they partially suppress immune function. You’ll be screened for tuberculosis before starting, because these drugs can reactivate latent TB. Regular blood monitoring continues throughout treatment.
Treating Gout and Crystal Arthritis
Gout is a form of inflammatory arthritis caused by uric acid crystals forming in joints when blood levels get too high. Crystals begin to form once uric acid exceeds roughly 6.4 mg/dL, which is the body’s natural saturation point. Treatment has two phases: stopping acute flares and then lowering uric acid levels long-term to dissolve existing crystals and prevent new ones.
For long-term management, the target is getting your uric acid below 6 mg/dL. If you have visible deposits of crystite (called tophi), chronic gouty arthritis, or frequent flares despite reaching that threshold, a more aggressive target below 5 mg/dL helps dissolve crystal deposits faster. Reaching and maintaining these levels with urate-lowering therapy prevents future attacks and gradually clears crystals from your joints over months to years.
Exercise and Joint Protection
Physical activity is a core part of managing inflammatory arthritis, but timing and intensity matter. When a joint is actively inflamed (hot, swollen, painful at rest), you should avoid strength training that joint until the inflammation settles. Water-based exercise is often a better choice during flares because buoyancy reduces stress on joints while still allowing you to maintain range of motion and fitness.
Once inflammation is controlled, resistance training is both safe and beneficial. It strengthens the muscles around your joints, which improves stability and reduces load on damaged cartilage. The key principles: work within a comfortable range of motion, stop any exercise that causes significant pain, and build up gradually. Aerobic exercise like walking, cycling, or swimming also reduces systemic inflammation and helps counter the fatigue that often accompanies inflammatory arthritis.
The Role of Diet and Supplements
Omega-3 fatty acids from fish oil have genuine anti-inflammatory effects, but the doses needed are higher than what most people take. Research indicates you need 3 to 5 grams per day of combined EPA and DHA to produce a measurable anti-inflammatory effect. That’s roughly 3 to 5 standard fish oil capsules, depending on concentration. At these doses, some people experience enough improvement to reduce their need for anti-inflammatory painkillers, though omega-3s are not a replacement for DMARDs.
For gout specifically, dietary changes play a meaningful supporting role. Reducing alcohol (especially beer), sugary drinks, and purine-rich foods like organ meats helps lower uric acid levels. But diet alone rarely brings uric acid below target, so most people with recurrent gout still need medication.
When Surgery Becomes an Option
Joint replacement is reserved for advanced, end-stage joint disease where cartilage is essentially gone and the joint no longer functions well. The decision isn’t based on imaging alone. It centers on how much arthritis is affecting your quality of life: whether pain is disabling, whether you’ve lost meaningful function, and whether non-surgical treatments have been exhausted. Hips and knees are the most commonly replaced joints, but shoulders, elbows, and small joints in the hands can also be addressed surgically when needed.
With modern treatment, fewer people with inflammatory arthritis reach the point of needing joint replacement than in previous decades. Early, aggressive use of DMARDs and biologics has dramatically reduced the rate of severe joint destruction, which is another reason why starting effective treatment early matters so much.